Immunotherapy plus chemo for advanced bile duct or gallbladder cancer
Part of Cancer clinical trials.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with advanced bile duct or gallbladder cancer that cannot be cured with surgery or local treatments.
- You are able to take care of yourself (ECOG performance status 0 or 1).
- You are expected to live at least 12 more weeks.
- Your major organs (like liver, kidneys, bone marrow) are working well enough.
- You do not have an active autoimmune disease or a history of one (like lupus, rheumatoid arthritis, or severe asthma needing daily medication).
- You have not had a serious bleeding event or blood clot in the last 3–6 months.
- You are not allergic to the study drugs (gemcitabine, cisplatin, or platinum).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a drug that blocks blood vessel growth (anti-angiogenic therapy) after immunotherapy can help people with advanced bile duct, gallbladder, or cholangiocarcinoma that cannot be removed by surgery. The goal is to see if this sequence improves outcomes for patients who have not had prior treatment for advanced disease.
This trial tests whether adding immunotherapy and targeted therapy to standard chemotherapy can help treat intrahepatic cholangiocarcinoma (a type of bile duct cancer). It is for patients who are starting treatment with one of two specific chemo regimens, possibly combined with the new drugs.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
This trial tests a new combination of immunotherapy (tislelizumab), radiation, and chemotherapy before surgery for people with bile duct cancer that is hard to remove. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.